Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
age-related macular degeneration
Biotech
Otsuka pens $420M deal for Asia rights to 4DMT gene therapy
4DMT has sold the Asia-Pacific rights to its eye gene therapy to Otsuka, securing $85 million in cash to fund the asset’s phase 3 development.
James Waldron
Oct 31, 2025 5:09am
Fatty acid eye injections restore vision in old mice
Sep 26, 2025 2:10pm
Eye disease biotech launches with $100M, Roche rival in clinic
Sep 17, 2025 6:30am
Alcon to buy LumiThera’s light-based therapy for dry AMD
Jul 8, 2025 10:30am
NIH creates eye drops that protect mice from vision loss
Mar 25, 2025 3:10pm
Eye disease biotech looks to clinical trials with $93M series B
Mar 25, 2025 8:00am
